Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients

Leukemia Research

Volumn 34, Issue 7, 2010, Pages 942-945

  Damiani, Daniela ^a,b   Tiribelli, Mario ^a,b   Michelutti, Angela ^a   Geromin, Antonella ^a   Cavallin, Margherita ^a   Fabbro, Dora ^a   Pianta, Annalisa ^a,b   Malagola, Michele ^c   Damante, Giuseppe ^a,b   Russo, Domenico ^c   Fanin, Renato ^a,b  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c SPEDALI CIVILI   (Italy)

Author keywords

Acute myeloid leukemia; BCRP; Fludarabine; Induction therapy; Prognosis

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTARABINE; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG MEGADOSE; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MUTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

EID: 77952911036     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.01.008     Document Type: Article

References (19)

1. Michieli M., Damiani D., Ermacora A., et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Brit J Haematol 1999, 104:328-335.
2. Leith C.P., Kopecky K.J., Chen I.M., et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999, 94:1086-1099.
3. Doyle L.A., Yang W., Abruzzo L.V., et al. Multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998, 95:15665-15670.
4. Litman T., Brangi M., Hudson E., et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000, 113:2011-2021.
5. Benderra Z., Faussat A.M., Sayada L., et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004, 10:7896-7902.
6. Damiani D., Tiribelli M., Calistri E., et al. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 2006, 91:825-828.
7. van den Heuvel-Eibrink M.M., van der Holt B., Burnett A.K., et al. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol 2006, 86:329-337.
8. Russo D., Malagola M., de Vivo A., et al. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. Brit J Haematol 2005, 131:172-179.
9. Malagola M., Damiani D., Martinelli G., et al. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. Brit J Haematol 2007, 136:87-95.
10. Mitelman F. ISCN: an international system for human cytogenetic nomenclature 1995, S. Karger, Basel, Switzerland.
11. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
12. Noguera N.I., Breccia M., Divona M., et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 2002, 16:2185-2189.
13. Cox C., Reeder J.E., Robinson R.D., et al. Comparison of frequency distribution in flow cytometry. Cytometry 1988, 9:291-298.
14. Kaplan E.R., Meier P. Non parametric estimation from incomplete observation. J Am Stat Ass 1958, 53:457-481.
15. Cox D.R. Regression models and life tables. J R Stat Soc 1972, 34:187-220.
16. Estey E.H., Thall P.F., Cortes J.E., et al. Comparison of idarubicin+ara-C-, fludarabine+ara-C-, and topotecan+ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001, 98:3575-3583.
17. Steinbach D., Legrand O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?. Leukemia 2007, 21:1172-1176.
18. Benderra Z., Faussat A.M., Sayada L., et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 2005, 11:7764-7772.
19. Abbott B.L., Colapietro A.M., Barnes Y., Marini F., Andreeff M., Sorrentino B.P. Low levels of ABCG2 expression in adult AML blast samples. Blood 2002, 100:4594-4601.